JP2019196370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019196370A5 JP2019196370A5 JP2019124501A JP2019124501A JP2019196370A5 JP 2019196370 A5 JP2019196370 A5 JP 2019196370A5 JP 2019124501 A JP2019124501 A JP 2019124501A JP 2019124501 A JP2019124501 A JP 2019124501A JP 2019196370 A5 JP2019196370 A5 JP 2019196370A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- use according
- effective amount
- therapeutically effective
- ranges
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 108050003475 Neuregulin Proteins 0.000 claims 8
- 102000014413 Neuregulin Human genes 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108050002150 EGF-like domains Proteins 0.000 claims 1
- 102000012545 EGF-like domains Human genes 0.000 claims 1
- 101001109800 Homo sapiens Pro-neuregulin-1, membrane-bound isoform Proteins 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000010005 growth-factor like effect Effects 0.000 claims 1
- 102000055650 human NRG1 Human genes 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021179961A JP2022023208A (ja) | 2008-07-17 | 2021-11-04 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13517108P | 2008-07-17 | 2008-07-17 | |
| US61/135,171 | 2008-07-17 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017150365A Division JP2017200949A (ja) | 2008-07-17 | 2017-08-03 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021179961A Division JP2022023208A (ja) | 2008-07-17 | 2021-11-04 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019196370A JP2019196370A (ja) | 2019-11-14 |
| JP2019196370A5 true JP2019196370A5 (enExample) | 2020-02-20 |
Family
ID=42005671
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518734A Expired - Fee Related JP5797112B2 (ja) | 2008-07-17 | 2009-07-17 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
| JP2015013248A Expired - Fee Related JP6189879B2 (ja) | 2008-07-17 | 2015-01-27 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
| JP2017150365A Pending JP2017200949A (ja) | 2008-07-17 | 2017-08-03 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
| JP2019124501A Pending JP2019196370A (ja) | 2008-07-17 | 2019-07-03 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
| JP2021179961A Pending JP2022023208A (ja) | 2008-07-17 | 2021-11-04 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518734A Expired - Fee Related JP5797112B2 (ja) | 2008-07-17 | 2009-07-17 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
| JP2015013248A Expired - Fee Related JP6189879B2 (ja) | 2008-07-17 | 2015-01-27 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
| JP2017150365A Pending JP2017200949A (ja) | 2008-07-17 | 2017-08-03 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021179961A Pending JP2022023208A (ja) | 2008-07-17 | 2021-11-04 | 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20110166068A1 (enExample) |
| EP (3) | EP3338791B1 (enExample) |
| JP (5) | JP5797112B2 (enExample) |
| CN (3) | CN102159236A (enExample) |
| AU (3) | AU2009292216B2 (enExample) |
| BR (1) | BRPI0916442A2 (enExample) |
| CA (1) | CA2731113A1 (enExample) |
| DK (2) | DK2320933T3 (enExample) |
| ES (2) | ES2763184T3 (enExample) |
| MX (2) | MX384378B (enExample) |
| PL (2) | PL3338791T3 (enExample) |
| RU (4) | RU2536938C2 (enExample) |
| WO (1) | WO2010030317A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2320933T3 (en) | 2008-07-17 | 2018-04-16 | Acorda Therapeutics Inc | THERAPEUTIC DOSAGE OF A NEUREGULIN OR A SUBSEQUENT THEREOF FOR TREATMENT OR PROPHYLAXY OF HEART FAILURE |
| EP3173091B1 (en) | 2008-08-15 | 2020-07-22 | Acorda Therapeutics, Inc. | Compositions and methods for treatment during non-acute periods following cns neurological injury |
| EP2808339B1 (en) * | 2008-11-28 | 2017-02-15 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neuregulin peptides and their use |
| PL2488194T3 (pl) | 2009-10-14 | 2016-11-30 | Zastosowanie neureguliny do leczenia uszkodzenia nerwu jamistego | |
| WO2013053076A1 (en) * | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| AU2013237896B2 (en) * | 2012-03-30 | 2017-11-02 | Acorda Therapeutics, Inc. | Use of neuregulin to treat peripheral nerve injury |
| CA2904055A1 (en) | 2013-03-06 | 2014-09-12 | Acorda Therapeutics, Inc. | Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure |
| CA2911848A1 (en) | 2013-05-22 | 2014-11-27 | Zensun (Shanghai) Science & Technology, Ltd. | Extended release of neuregulin for treating heart failure |
| CN110946993A (zh) | 2014-01-03 | 2020-04-03 | 上海泽生科技开发股份有限公司 | 纽兰格林制剂的配方 |
| CN105561298A (zh) * | 2014-10-17 | 2016-05-11 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
| CA2999301A1 (en) | 2015-09-25 | 2017-03-30 | Douglas B. Sawyer | Methods for treating cardiac injury |
| CN108778315A (zh) * | 2016-04-19 | 2018-11-09 | 莱布尼茨研究所-针对老化研究(弗里茨利普曼研究所) | 用于治疗和/或预防神经系统肿瘤的神经调节素 |
| CN110835368A (zh) * | 2018-08-15 | 2020-02-25 | 上海泽生科技开发股份有限公司 | 神经调节蛋白多肽片段及其用途 |
| AR121035A1 (es) | 2019-04-01 | 2022-04-13 | Lilly Co Eli | Compuestos de neuregulina-4 y métodos de uso |
| JP2022547335A (ja) * | 2019-09-16 | 2022-11-11 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． | 組換えヒトニューレグリン誘導体及びその使用 |
| WO2023070078A1 (en) * | 2021-10-22 | 2023-04-27 | The Research Institute At Nationwide Children's Hospital | Neuregulin for protection against respiratory viral infection and post-viral disease |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716930A (en) | 1991-04-10 | 1998-02-10 | Ludwig Institute For Cancer Research | Glial growth factors |
| US5530109A (en) | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
| US7115554B1 (en) * | 1993-05-06 | 2006-10-03 | Acorda Therapeutics, Inc. | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
| US6087323A (en) | 1992-04-03 | 2000-07-11 | Cambridge Neuroscience, Inc. | Use of neuregulins as modulators of cellular communication |
| US7037888B1 (en) | 1992-04-03 | 2006-05-02 | Acorda Therapeutics, Inc. | Methods for treating muscle diseases and disorders |
| US5811098A (en) * | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
| US5912326A (en) | 1995-09-08 | 1999-06-15 | President And Fellows Of Harvard College | Cerebellum-derived growth factors |
| US6136558A (en) * | 1997-02-10 | 2000-10-24 | Genentech, Inc. | Heregulin variants |
| US6051401A (en) | 1998-07-28 | 2000-04-18 | Bayer Corporation | Methods and constructs for protein expression |
| US6468967B1 (en) | 1998-09-25 | 2002-10-22 | Cubist Pharmaceuticals, Incorporated | Methods for administration of antibiotics |
| AUPP785098A0 (en) * | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| US6635249B1 (en) * | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
| CN1138785C (zh) * | 1999-06-04 | 2004-02-18 | 周明东 | 生长因子神经调节蛋白及其类似物的新应用 |
| AU1916301A (en) | 1999-11-12 | 2001-06-06 | Children's Medical Center Corporation | Methods for administration of therapeutic agents on an antiangiogenic schedule |
| AU2001274947B2 (en) | 2000-05-23 | 2006-08-17 | Acorda Therapeutics, Inc. | Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| CU23157A1 (es) * | 2001-01-03 | 2006-07-18 | Ct Ingenieria Genetica Biotech | COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL |
| AU2003210549A1 (en) | 2002-01-18 | 2003-09-02 | Chiron Corporation | Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein |
| WO2003099320A1 (en) | 2002-05-24 | 2003-12-04 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
| EP1848434A2 (en) * | 2005-02-18 | 2007-10-31 | Orion Corporation | A method for treating heart failure |
| AR053690A1 (es) | 2005-03-23 | 2007-05-16 | Pfizer Prod Inc | Terapia de cancer de prostata con anticuerpos contra ctla4 y terapia hormonal |
| CA2658326C (en) | 2005-09-02 | 2013-04-23 | Morehouse School Of Medicine | Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue |
| US20070213264A1 (en) * | 2005-12-02 | 2007-09-13 | Mingdong Zhou | Neuregulin variants and methods of screening and using thereof |
| BRPI0620819A2 (pt) * | 2005-12-30 | 2011-11-22 | Zensun Shangai Science & Technology Ltd | uso de uma neuregulina (nrg) de liberação prolongada, nrg em uma liberação prolongada de uma dosagem baixa constante, e, composição de liberação prolongada para prevenir, tratar ou retardar uma doença ou distúrbio em um mamìfero |
| ES2811127T3 (es) | 2008-02-29 | 2021-03-10 | Acorda Therapeutics Inc | Composiciones para lograr niveles plasmáticos deseados del factor 2 de crecimiento glial |
| DK2320933T3 (en) | 2008-07-17 | 2018-04-16 | Acorda Therapeutics Inc | THERAPEUTIC DOSAGE OF A NEUREGULIN OR A SUBSEQUENT THEREOF FOR TREATMENT OR PROPHYLAXY OF HEART FAILURE |
| PL2488194T3 (pl) | 2009-10-14 | 2016-11-30 | Zastosowanie neureguliny do leczenia uszkodzenia nerwu jamistego | |
| JP2013535507A (ja) | 2010-08-13 | 2013-09-12 | ジョージタウン ユニバーシティ | Ｇｇｆ２および使用方法 |
| AU2013237896B2 (en) | 2012-03-30 | 2017-11-02 | Acorda Therapeutics, Inc. | Use of neuregulin to treat peripheral nerve injury |
-
2009
- 2009-07-17 DK DK09813336.6T patent/DK2320933T3/en active
- 2009-07-17 CN CN2009801360798A patent/CN102159236A/zh active Pending
- 2009-07-17 DK DK17209369.2T patent/DK3338791T3/da active
- 2009-07-17 RU RU2011105821/10A patent/RU2536938C2/ru active
- 2009-07-17 MX MX2015001826A patent/MX384378B/es unknown
- 2009-07-17 WO PCT/US2009/004130 patent/WO2010030317A2/en not_active Ceased
- 2009-07-17 CA CA2731113A patent/CA2731113A1/en not_active Abandoned
- 2009-07-17 BR BRPI0916442-1A patent/BRPI0916442A2/pt not_active IP Right Cessation
- 2009-07-17 EP EP17209369.2A patent/EP3338791B1/en active Active
- 2009-07-17 PL PL17209369T patent/PL3338791T3/pl unknown
- 2009-07-17 ES ES17209369T patent/ES2763184T3/es active Active
- 2009-07-17 MX MX2011000696A patent/MX2011000696A/es active IP Right Grant
- 2009-07-17 JP JP2011518734A patent/JP5797112B2/ja not_active Expired - Fee Related
- 2009-07-17 AU AU2009292216A patent/AU2009292216B2/en not_active Ceased
- 2009-07-17 EP EP09813336.6A patent/EP2320933B1/en not_active Not-in-force
- 2009-07-17 ES ES09813336.6T patent/ES2664394T3/es active Active
- 2009-07-17 US US13/055,397 patent/US20110166068A1/en not_active Abandoned
- 2009-07-17 EP EP19197381.7A patent/EP3632459A1/en not_active Withdrawn
- 2009-07-17 CN CN201510010273.9A patent/CN104623633A/zh active Pending
- 2009-07-17 CN CN201710109733.2A patent/CN107019794B/zh not_active Expired - Fee Related
- 2009-07-17 PL PL09813336T patent/PL2320933T3/pl unknown
-
2013
- 2013-05-29 US US13/904,654 patent/US9198951B2/en active Active
-
2014
- 2014-10-14 RU RU2014141514A patent/RU2698090C2/ru active
-
2015
- 2015-01-27 JP JP2015013248A patent/JP6189879B2/ja not_active Expired - Fee Related
- 2015-05-27 AU AU2015202877A patent/AU2015202877B2/en not_active Ceased
- 2015-10-30 US US14/928,124 patent/US9956266B2/en active Active
-
2017
- 2017-05-26 AU AU2017203528A patent/AU2017203528A1/en not_active Abandoned
- 2017-08-03 JP JP2017150365A patent/JP2017200949A/ja active Pending
-
2018
- 2018-03-29 US US15/940,250 patent/US20180280477A1/en not_active Abandoned
-
2019
- 2019-07-03 JP JP2019124501A patent/JP2019196370A/ja active Pending
- 2019-08-12 RU RU2019125376A patent/RU2719199C1/ru active
- 2019-09-09 US US16/564,739 patent/US11235031B2/en active Active
-
2020
- 2020-03-18 RU RU2020111236A patent/RU2020111236A/ru unknown
-
2021
- 2021-11-04 JP JP2021179961A patent/JP2022023208A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019196370A5 (enExample) | ||
| RU2020111236A (ru) | Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности | |
| JP2016516016A5 (enExample) | ||
| JP2022031772A5 (enExample) | ||
| JP2015187125A5 (enExample) | ||
| JP2016514132A5 (enExample) | ||
| US20080213288A1 (en) | Combined Use Of A Modulator Of CD3 And A GLP-1 Compound | |
| HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
| JP2013533858A5 (enExample) | ||
| RU2014101207A (ru) | Новые показания к применению при лечении антителами против il-1-бета | |
| JP2011507860A5 (enExample) | ||
| FI3356386T3 (fi) | Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä | |
| US20250177364A1 (en) | Combination therapies for breast cancer | |
| JP2014500278A5 (enExample) | ||
| JP2005506345A5 (enExample) | ||
| RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
| CA2944811C (en) | Combination therapy for the treatment of autoimmune diseases | |
| RU2009118962A (ru) | Применение антагонистов il-1 для лечения подагры и псевдоподагры | |
| JP2019521156A5 (enExample) | ||
| JP2022035920A5 (enExample) | ||
| EP1450850B1 (en) | Method of administering a thymosin alpha 1 peptide | |
| JP2005529152A5 (enExample) | ||
| JP2020510028A5 (enExample) | ||
| JP2009538916A5 (enExample) | ||
| RU2018132694A (ru) | Фармацевтическая композиция, включающая рекомбинантный гормон роста человека для лечения дефицита гормона роста |